Smart jab can shrink head and neck cancer tumours within six weeks, trial finds

19 octobre 2025 | Andrew Gregory Health editor
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks. Head and neck (…)
 Site référencé:  The Guardian (South&CentralAsia)

The Guardian (South&CentralAsia) 

Lily King : ‘What is life without love ?’
19/10/2025
Should we treat environmental crime more like murder ?
19/10/2025
Woman investigated over husband’s use of assisted dying clinic wanted to argue case in court
19/10/2025
Scottish hospitality coalition urges chancellor to protect whisky industry
19/10/2025
Experiential entertainment is having a gold rush but commercial success is far from certain
19/10/2025
What’s happening with Marjorie Taylor Greene ? Why the Maga loyalist has won some Democratic fans
19/10/2025